SenoMune-0257 is a nine-amino-acid peptide from Immorta Bio, still preclinical. What the company reported on 12 October 2026, and what it has not.
SenoMune-0257 is a synthetic peptide of nine amino acids, announced by the Miami biotechnology company Immorta Bio on 12 October 2026. The company says artificial intelligence helped to identify it and that it is designed to prompt T cells to recognise and remove senescent cells. Immorta describes it as investigational.
The company says it has finished its planned preclinical laboratory studies. In those studies, it reports, the peptide stimulated cytotoxic T cells that removed senescent cells and spared healthy ones "under the conditions tested". The announcement names no assays and gives no sample sizes. It cites no peer-reviewed paper on SenoMune-0257 itself. Durable immune memory and lower off-target toxicity are stated design goals, and the announcement gives no data for them.
Senolytics are small molecules that kill senescent cells directly. Immorta says experimental small-molecule senolytics face potential off-target toxicity and cannot generate durable immune memory. A peptide that directs the body's own T cells is its proposed alternative. It builds on the company's earlier SenoVax cellular immunotherapy and is described as a simpler product that could potentially be made off the shelf. Our explainer covers senolytics and senescent cells in more detail.
Immorta says it is preparing to enter the clinic, with initial human evaluation expected before the end of 2026. It names no trial design and no regulatory filing. It also states that safety and efficacy have not been established in humans. Until results appear in a journal, every efficacy statement is a company claim. For wider ageing research, see our NAD+ research overview.
Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.
We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.
How NAD+ differs from NADH, NADP+, NMN and NR, and which material and analytical details are needed when reading a laboratory listing.
ResearchSenolytics selectively trigger cell death in senescent 'zombie' cells. What senescent cells are, how senolytics are classified, and where immunity fits.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.